Premium
Long‐term outcomes of donation after cardiac death liver allografts from a single center
Author(s) -
Nguyen Justin H.,
Bonatti Hugo,
Dickson Rolland C.,
Hewitt Winston R.,
Grewal Hani P.,
Willingham Darrin L.,
Harnois Denise M.,
Schmitt Timothy M.,
Machicao Victor I.,
Ghabril Marwan S.,
Keaveny Andrew P.,
ArandaMichel Jaime,
Satyanarayana Raj,
Rosser Barry G.,
Hinder Ronald A.,
Steers Jeffery L.,
Hughes Christopher B.
Publication year - 2009
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2009.00968.x
Subject(s) - medicine , single center , economic shortage , liver transplantation , surgery , organ donation , donation , cardiac function curve , transplantation , heart failure , linguistics , philosophy , government (linguistics) , economics , economic growth
Organ shortage continues to be a major challenge in transplantation. Recent experience with controlled non‐heart‐beating or donation after cardiac death (DCD) are encouraging. However, long‐term outcomes of DCD liver allografts are limited. In this study, we present outcomes of 19 DCD liver allografts with follow‐up >4.5 years. During 1998–2001, 19 (4.1%) liver transplants (LT) with DCD allografts were performed at our center. Conventional heart‐beating donors included 234 standard criteria donors (SCD) and 214 extended criteria donors (ECD). We found that DCD allografts had equivalent rates of primary non‐function and biliary complications as compared with SCD and ECD. The overall one‐, two‐, and five‐yr DCD graft and patient survival was 73.7%, 68.4%, and 63.2%, and 89.5%, 89.5%, and 89.5%, respectively. DCD graft survival was similar to graft survival of SCD and ECD in non hepatitis C virus (HCV) recipients (p > 0.370). In contrast, DCD graft survival was significantly reduced in HCV recipients (p = 0.007). In conclusion, DCD liver allografts are durable and have acceptable long‐term outcomes. Further research is required to assess the impact of HCV on DCD allograft survival.